DE60119696D1 - NALOXONE AND NALTREXONE ANALOGUES IN THE TREATMENT OF DRUG ABUSE - Google Patents

NALOXONE AND NALTREXONE ANALOGUES IN THE TREATMENT OF DRUG ABUSE

Info

Publication number
DE60119696D1
DE60119696D1 DE60119696T DE60119696T DE60119696D1 DE 60119696 D1 DE60119696 D1 DE 60119696D1 DE 60119696 T DE60119696 T DE 60119696T DE 60119696 T DE60119696 T DE 60119696T DE 60119696 D1 DE60119696 D1 DE 60119696D1
Authority
DE
Germany
Prior art keywords
treatment
naltrexone
naloxone
analogs
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60119696T
Other languages
German (de)
Other versions
DE60119696T2 (en
Inventor
Wolfgang Sadee
Danxin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22697044&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60119696(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of DE60119696D1 publication Critical patent/DE60119696D1/en
Application granted granted Critical
Publication of DE60119696T2 publication Critical patent/DE60119696T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of naltrexone and naloxone analogs, which are neutral antagonists at the mu opioid receptor, for the treatment of drug dependency in a drug-dependent individual. Surprisingly, it has been found that administration of a therapeutically effect amount of the naloxone or naltrexone analogs described herein for the treatment of a drug dependency, can result in reduction of undesirable side effects resulting from current treatments using naloxone and naltrexone. For example, the treatment described herein can result in a reduction in the withdrawal symptoms and aversion encountered in the use of naloxone and naltrexone in the treatment of drug dependency. In addition, the naltrexone and naloxone analogs of the invention can be used for the treatment of pain in an individual in need thereof by modulating opoid pain treatment using neutral antagonists, for example, reversing respiratory depression withough causing other adverse effects. In addition, during chronic use of opioid drugs for pain therapy, neutral antagonists can be used to diminish constipation peripherally without effecting the central analgesic effects.
DE60119696T 2000-03-15 2001-03-15 NALOXONE AND NALTREXONE ANALOGUES IN THE TREATMENT OF DRUG ABUSE Expired - Lifetime DE60119696T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18937200P 2000-03-15 2000-03-15
US189372P 2000-03-15
PCT/US2001/008225 WO2001068080A2 (en) 2000-03-15 2001-03-15 Neutral antagonists and use thereof in treating drug abuse

Publications (2)

Publication Number Publication Date
DE60119696D1 true DE60119696D1 (en) 2006-06-22
DE60119696T2 DE60119696T2 (en) 2007-01-25

Family

ID=22697044

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60119696T Expired - Lifetime DE60119696T2 (en) 2000-03-15 2001-03-15 NALOXONE AND NALTREXONE ANALOGUES IN THE TREATMENT OF DRUG ABUSE

Country Status (7)

Country Link
US (2) US20010049375A1 (en)
EP (1) EP1263438B1 (en)
AT (1) ATE326222T1 (en)
AU (1) AU4743601A (en)
CA (1) CA2403252A1 (en)
DE (1) DE60119696T2 (en)
WO (1) WO2001068080A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
PT1041987E (en) 1997-12-22 2006-07-31 Euro Celtique Sa PHARMACEUTICAL FORM OF ORAL DOSAGE, UNDERSTANDING A COMBINATION OF AN AGRONIST OF OPIOIDE AND NALTREXONE
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
ATE419039T1 (en) 2001-07-18 2009-01-15 Euro Celtique Sa PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE
RU2004106619A (en) 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) COMPOSITIONS OF AN OPIOID AGONIST CONTAINING A RELEASABLE AND ISOLATED ANTAGONIST
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
EP2939696B1 (en) * 2001-10-18 2016-03-09 Nektar Therapeutics Polymer conjugates of opioid antagonists
DE10161963A1 (en) * 2001-12-17 2003-07-03 Johannes Schuetz 6-aminomorphine derivatives, production process therefor and their use
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
ES2733051T1 (en) 2002-04-05 2019-11-27 Euro Celtique Sa Matrix for sustained, invariable and independent release of active compounds
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
JP4545584B2 (en) 2002-05-17 2010-09-15 デューク ユニバーシティ Methods for treating obesity
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
PT2316456T (en) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
NZ583573A (en) * 2003-12-16 2011-12-22 Nektar Therapeutics Pegylated naloxol
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (en) * 2004-01-13 2007-05-29 Univ Duke Anticonvulsant and antipsychotic drug compositions and methods for their use to affect weight loss
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20070197573A1 (en) * 2005-10-04 2007-08-23 Wolfgang Sadee Compositions and methods in the treatment of bone metabolic disorders
DK2135603T3 (en) 2005-11-22 2013-03-25 Orexigen Therapeutics Inc Compositions and Methods for Increasing Insulin Sensitivity
CN1813740B (en) * 2005-11-22 2010-05-05 岳振江 Sublingual pellicles containing naloxone hydrochloride and preparing method thereof
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20150029762A (en) 2006-06-19 2015-03-18 알파마 파머슈티컬스 엘엘씨 Pharmaceutical compositions
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
CN101588795A (en) 2006-11-09 2009-11-25 奥雷西根治疗公司 Wo2008055686
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2148933A4 (en) * 2007-04-30 2010-05-19 Univ Ohio State Res Found Polymorphisms in genes affecting dopamine transporter disorders and uses thereof
US8883817B2 (en) 2007-10-18 2014-11-11 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20110144145A1 (en) * 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
WO2011139525A1 (en) * 2010-05-05 2011-11-10 Philadelphia Health & Education Corporation Stereoisomer of naloxone and potential therapeutic action of opioid drugs to reverse clinical tolerance to these agents
EP2630150B1 (en) 2010-10-19 2017-04-12 Memorial Sloan-Kettering Cancer Center 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US9938576B1 (en) 2012-09-21 2018-04-10 Ohio State Innovation Foundation Materials and methods for determining metabolizer status in humans
MY183489A (en) 2013-07-23 2021-02-22 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CN116059376A (en) 2014-05-30 2023-05-05 纽约州立大学研究基金会 Compositions and methods for promoting bone formation
US11046692B2 (en) 2015-04-30 2021-06-29 Memorial Sloan-Kettering Cancer Center Mitragynine analogs and uses thereof
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
CN108778423A (en) * 2016-01-08 2018-11-09 俄亥俄州国家创新基金会 The treatment and prevention of opiates neonatal abstinence syndrome
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2020142644A1 (en) * 2019-01-04 2020-07-09 Aether Therapeutics Inc. Method for treating drug or alcohol dependency
EP3999068A1 (en) 2019-07-15 2022-05-25 Rovaxa Opioid growth factor receptor (ogfr) antagonists, in particular naloxone and/or naltrexone for treating cancer
EP4366736A1 (en) * 2021-07-06 2024-05-15 Aether Therapeutics Inc. Low-dose naltrexol and uses thereof
US11957676B1 (en) * 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254088A (en) 1961-03-14 1966-05-31 Lewenstein Morphine derivative
NL137652C (en) 1962-07-11
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
BE744162A (en) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd ENCAPSULATION PROCESS
DE2010115A1 (en) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Process for the production of micro-granules
JPS523342B2 (en) 1972-01-26 1977-01-27
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4689332A (en) 1984-04-09 1987-08-25 Research Corporation Growth regulation and related applications of opioid antagonists
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4816586A (en) 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5051426A (en) 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency
CH683005A5 (en) * 1991-10-30 1993-12-31 Aldo Massarotti Prepn. of N-oxide(s) of opioid analgesics and antagonists - for treating opiate drug addiction without prior art side effects, e.g. 6-di:methylamino 4,4-di:phenyl 3-heptanone N-oxide
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
USRE36547E (en) 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6007986A (en) 1993-06-23 1999-12-28 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic activity screening
US5882944A (en) 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
WO1996014071A1 (en) * 1994-11-04 1996-05-17 Legarda Ibanez Juan Jose Combination of chemical compounds used as a medicament intended to suppress the dependence of individuals to opioids
AU5374996A (en) 1995-03-31 1996-10-16 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
WO1997033581A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5760044A (en) * 1996-05-16 1998-06-02 Archer; Sydney Method for treating ***e and amphetamine dependency
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
CA2290788A1 (en) * 1997-05-20 1998-11-26 Suchitra Krishnan-Sarin Substance dependence treatment using opiate antagonists and serotonin compounds
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6109269A (en) 1999-04-30 2000-08-29 Medtronic, Inc. Method of treating addiction by brain infusion

Also Published As

Publication number Publication date
US20030069262A1 (en) 2003-04-10
EP1263438B1 (en) 2006-05-17
ATE326222T1 (en) 2006-06-15
US20010049375A1 (en) 2001-12-06
EP1263438A2 (en) 2002-12-11
US6713488B2 (en) 2004-03-30
AU4743601A (en) 2001-09-24
CA2403252A1 (en) 2001-09-20
DE60119696T2 (en) 2007-01-25
WO2001068080A2 (en) 2001-09-20
WO2001068080A3 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
DE60119696D1 (en) NALOXONE AND NALTREXONE ANALOGUES IN THE TREATMENT OF DRUG ABUSE
WO2003070191A3 (en) Tamper-resistant transdermal opioid delivery devices
WO2004017941A3 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
CA2302754A1 (en) Noribogaine in the treatment of pain and drug addiction
CY1107262T1 (en) TREATMENT OF DEPENDENCE ADDITION
NO20001175D0 (en) Painkillers comprising anti-epileptic compounds and methods of use thereof
KR970009799A (en) Treatment of substance abuse withdrawal
WO2002058620A3 (en) Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
Moriel et al. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction
PT1656131E (en) Use of betaine for treating intermittent claudication
HUP0203466A2 (en) Synergic combination of an nk1 receptor antagonist and a gaba structural analog and pharmaceutical composition containing it and use thereof
SE9902597D0 (en) New use
WO2007059445A3 (en) Synergistic combinations of norketamine and opioid analgesics
JP7244992B2 (en) Combinations of opioids and N-acylethanolamines
Komoda et al. Enhancement of lidocaine-induced epidural anesthesia by deoxyaconitine in the rabbit
CA2333076A1 (en) Topical application of muscarinic analgesic drugs such as neostigmine
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
HUP9801628A2 (en) Therapeutic composition for arthritis
US20040198723A1 (en) Method of treatment
MD1610F1 (en) Method of the recidivating chronic aphthous stomatitis treatment
HK1039751A1 (en) Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manfacture of a medicament for intraspinal, intrathecal or epidural administration
Anderson Know your options: Choosing among analgesics
HUP0301026A2 (en) Use of arginine the preparation of a medicament for the prevention and treatment the side effects associated with the intravenous administration of pharmaceuticals

Legal Events

Date Code Title Description
8364 No opposition during term of opposition